GEMMA Biotherapeutics
GEMMA Biotherapeutics is a Philadelphia-based biotech startup focused on accelerating gene therapy research for rare diseases. The company raised $34M in seed funding in December 2024 and employs 66 people.
The growth story
GEMMA Biotherapeutics grew from 1 to 66 employees between 2023 and 2026, raising $34M along the way, most recently a Seed in December 2024.
About
GEMMA Biotherapeutics develops advanced gene therapies aimed at treating rare diseases, working alongside Franklin Biolabs to expedite research and global patient access. Its focus is on accelerating the delivery of these therapies to market.
The company launched in 2024 and quickly secured $34M in seed funding, positioning it as a notable new player in the gene therapy space. With 66 employees, it is building a research-focused team to advance its mission.
Founders and leadership
The company is led by a research-focused team, with 14 employees dedicated to research functions. Its leadership and operations are concentrated in Philadelphia, reflecting its academic and biotech roots.
The GEMMA Biotherapeutics org chart
James M. Wilson, MD, PhD (President and Chief Executive Officer) leads 39 mapped leaders with 5 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Research 21 (-25% YoY), Business Development 12 (0% YoY), Operations 4 (+33% YoY), Quality Assurance 4 (+33% YoY), Healthcare Services 3 (0% YoY), Information Technology 3 (-40% YoY).
Talent flow
GEMMA Biotherapeutics draws heavily from the University of Pennsylvania, with 37% of its talent coming from the university's Gene Therapy Program. Other top sources include GSK, Catalent, and Abbott, indicating a mix of academic and industry expertise. Alumni have moved to Franklin Biolabs, Ikigai BioVentures, and GRAIL, suggesting a network of biotech and venture capital connections.
Most common previous employers of GEMMA Biotherapeutics staff: Gene Therapy Program | University of Pennsylvania (37), University of Pennsylvania (10), University of Pennsylvania School of Medicine (5), GSK (4), Catalent (3), Abbott (3). Former GEMMA Biotherapeutics employees most often moved to Franklin Biolabs (6), Ikigai BioVentures (1), GRAIL (1), Rosemont Pharmaceuticals (1), Infinite Equity (1), ParetoHealth (1).
Alumni worth knowing
Web traffic
Traffic mix: 0% direct, 0% search, 0% social, 0% paid.
What this company is made of
Most common skills at GEMMA Biotherapeutics: Molecular Biology (23), Life Sciences (20), Research Skills (19), Biotechnology (19), Data Analysis (16), Biochemistry (16), Leadership (15), Project Management (15).
Where the team actually sits
GEMMA Biotherapeutics people are concentrated in Pennsylvania, United States (39), Greater Philadelphia (9), United Kingdom (2), Massachusetts, United States (2).
Search footprint
GEMMA Biotherapeutics attracts about 71 organic search visits a month, traffic worth roughly $1K a month if bought through ads. It gained 12 ranking keywords and lost 9 in the last period.
Frequently asked
GEMMA Biotherapeutics has 66 employees as of September 2026.
GEMMA Biotherapeutics has raised $34M in total, most recently a Seed round in December 2024.
James M. Wilson, MD, PhD (President and Chief Executive Officer) sits at the top of GEMMA Biotherapeutics's reporting structure, with 5 direct reports.
The most common previous employers of current GEMMA Biotherapeutics staff are Gene Therapy Program | University of Pennsylvania (37 people), University of Pennsylvania (10 people), University of Pennsylvania School of Medicine (5 people).
Former GEMMA Biotherapeutics employees most often move to Franklin Biolabs (6), Ikigai BioVentures (1), GRAIL (1).
GEMMA Biotherapeutics attracts about 71 organic search visits a month, worth roughly $1K a month in equivalent ad spend.
The most common skills among GEMMA Biotherapeutics staff are Molecular Biology, Life Sciences, Research Skills, Biotechnology, Data Analysis.
GEMMA Biotherapeutics staff are concentrated in Pennsylvania, United States (39), Greater Philadelphia (9), United Kingdom (2).
GEMMA Biotherapeutics has about 21 people in Research, down 25% over the past year, as of September 2026.
GEMMA Biotherapeutics has about 12 people in Business Development, up 0% over the past year, as of September 2026.
Computed from 59 current and 21 former GEMMA Biotherapeutics profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.